Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 1999

View Archived Issues

Avigen reports advances in gene therapy for hemophilia A

Biogen provides update on top three proprietary products

Recent significant events at P&U summarized

Elan plans clinical trials for AD treatment

EpiGenesis focuses on development of new class of respiratory agents

Company Profile: Actinova

Inhibitors of TNF-alpha production/release in early development at Sumitomo

Meiji Milk Products reveals new antiangiogenic agents

New imidazole compounds from Taisho/Sagami inhibit PDE1

Preparation and activity of apoptosis inducers disclosed by Takara Shuzo

Bristol-Myers Squibb begins phase II testing of inlicensed quinolone

Photogen teams up with Akorn to advance development of PH-10

Potent, broad-spectrum, orally bioavailable carbapenems designed by Sankyo

Integrin alphavbeta3 antagonist findings presented by Genentech team at AHA

SUN-N5030 emerges as potent neuroprotectant from new class of dual Na+/Ca2+ channel blockers

Preclinical data reported at ASN support utility of OP-1 in treating renal disease

Mixed AMPA and glycine-site NMDA antagonist with i.v./i.p. anticonvulsant activity

Positive findings of ACTION I study presented at ASN

Genetronics and Boehringer Ingelheim enter collaborative gene therapy agreement

Phase II data support further study of VX-497 for hepatitis C

United Therapeutics completes enrollment in phase III pulmonary hypertension trial

Major U.K. biopharmaceutical company merger announced

Xenova's lead drug candidates enter phase II trials during Q3 1999

AASLD presentations support feasibility of ribozyme therapy in HCV

SDZ-RAD inhibits HBV antigen production, transcription, unlike other immunosuppressants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...